Eric Michael Przybyszewski, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatorenal Syndrome | 2 | 2024 | 76 | 1.060 |
Why?
|
Liver Transplantation | 6 | 2024 | 2416 | 0.980 |
Why?
|
Liver Cirrhosis | 7 | 2024 | 1959 | 0.840 |
Why?
|
Waiting Lists | 2 | 2024 | 778 | 0.800 |
Why?
|
Vasoconstrictor Agents | 1 | 2024 | 655 | 0.690 |
Why?
|
Acute Kidney Injury | 4 | 2024 | 1946 | 0.660 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2024 | 1243 | 0.600 |
Why?
|
Hemangiosarcoma | 1 | 2020 | 214 | 0.600 |
Why?
|
Liver Neoplasms | 3 | 2024 | 4357 | 0.600 |
Why?
|
Liver Diseases, Alcoholic | 3 | 2023 | 162 | 0.540 |
Why?
|
Living Donors | 2 | 2018 | 647 | 0.530 |
Why?
|
End Stage Liver Disease | 4 | 2024 | 369 | 0.510 |
Why?
|
Rectum | 1 | 2020 | 898 | 0.500 |
Why?
|
Hepatitis C, Chronic | 1 | 2023 | 1032 | 0.490 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2024 | 2330 | 0.450 |
Why?
|
Hepatitis C | 1 | 2023 | 1594 | 0.420 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2020 | 1126 | 0.420 |
Why?
|
Hepatitis, Alcoholic | 2 | 2024 | 110 | 0.390 |
Why?
|
Pennisetum | 2 | 2021 | 3 | 0.320 |
Why?
|
Severity of Illness Index | 4 | 2024 | 15925 | 0.300 |
Why?
|
Graft Survival | 2 | 2018 | 3896 | 0.300 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4210 | 0.240 |
Why?
|
Graft Rejection | 1 | 2018 | 4498 | 0.240 |
Why?
|
Esophageal and Gastric Varices | 1 | 2024 | 215 | 0.200 |
Why?
|
Iron | 2 | 2021 | 1811 | 0.200 |
Why?
|
Alcoholism | 2 | 2023 | 1980 | 0.200 |
Why?
|
Ascites | 1 | 2023 | 336 | 0.190 |
Why?
|
Cholangitis, Sclerosing | 1 | 2021 | 179 | 0.170 |
Why?
|
Food, Fortified | 2 | 2021 | 189 | 0.150 |
Why?
|
Fatty Liver | 1 | 2024 | 811 | 0.140 |
Why?
|
Physical Exertion | 1 | 2020 | 667 | 0.140 |
Why?
|
Europe | 1 | 2024 | 3432 | 0.140 |
Why?
|
Histocompatibility | 1 | 2018 | 322 | 0.140 |
Why?
|
Efficiency | 1 | 2020 | 479 | 0.140 |
Why?
|
Hepacivirus | 1 | 2023 | 1342 | 0.130 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 561 | 0.130 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 614 | 0.130 |
Why?
|
Fathers | 1 | 2018 | 377 | 0.120 |
Why?
|
Natural Language Processing | 1 | 2024 | 1202 | 0.120 |
Why?
|
Lymphoproliferative Disorders | 1 | 2018 | 527 | 0.120 |
Why?
|
Iron, Dietary | 1 | 2015 | 148 | 0.110 |
Why?
|
Biopsy | 2 | 2024 | 6777 | 0.100 |
Why?
|
Patient Selection | 1 | 2024 | 4256 | 0.100 |
Why?
|
Antiviral Agents | 1 | 2023 | 3070 | 0.090 |
Why?
|
Proteomics | 1 | 2023 | 3913 | 0.080 |
Why?
|
Prognosis | 3 | 2024 | 29963 | 0.080 |
Why?
|
Energy Metabolism | 1 | 2020 | 2906 | 0.080 |
Why?
|
Humans | 19 | 2024 | 767040 | 0.080 |
Why?
|
Mothers | 1 | 2018 | 2209 | 0.070 |
Why?
|
Retrospective Studies | 8 | 2024 | 81659 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2024 | 65295 | 0.070 |
Why?
|
Tissue Donors | 1 | 2016 | 2387 | 0.070 |
Why?
|
Liver | 1 | 2020 | 7578 | 0.060 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2020 | 372 | 0.050 |
Why?
|
Middle Aged | 9 | 2024 | 223233 | 0.050 |
Why?
|
Male | 10 | 2024 | 364203 | 0.050 |
Why?
|
Renal Replacement Therapy | 1 | 2024 | 281 | 0.050 |
Why?
|
United States | 3 | 2024 | 72971 | 0.050 |
Why?
|
Endoscopy, Digestive System | 1 | 2024 | 358 | 0.050 |
Why?
|
Age Factors | 1 | 2018 | 18401 | 0.050 |
Why?
|
India | 2 | 2020 | 2334 | 0.050 |
Why?
|
Time Factors | 2 | 2024 | 40154 | 0.050 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 304 | 0.040 |
Why?
|
Alcohol Drinking | 2 | 2023 | 4045 | 0.040 |
Why?
|
Nutritional Status | 2 | 2020 | 1628 | 0.040 |
Why?
|
Necrosis | 1 | 2023 | 1614 | 0.040 |
Why?
|
Female | 10 | 2024 | 396660 | 0.040 |
Why?
|
Tea | 1 | 2020 | 289 | 0.040 |
Why?
|
Adolescent | 4 | 2021 | 89046 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2021 | 1104 | 0.040 |
Why?
|
Occupations | 1 | 2020 | 516 | 0.040 |
Why?
|
Fibroblast Growth Factors | 1 | 2023 | 873 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20741 | 0.030 |
Why?
|
Ethanol | 1 | 2023 | 1330 | 0.030 |
Why?
|
Infant | 1 | 2018 | 36485 | 0.030 |
Why?
|
Child | 3 | 2021 | 80771 | 0.030 |
Why?
|
Risk Factors | 2 | 2024 | 74886 | 0.030 |
Why?
|
Orosomucoid | 1 | 2015 | 45 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2021 | 2509 | 0.030 |
Why?
|
Child, Preschool | 1 | 2018 | 42606 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 21526 | 0.030 |
Why?
|
Donor Selection | 1 | 2016 | 242 | 0.030 |
Why?
|
Aged | 5 | 2024 | 171319 | 0.030 |
Why?
|
Algorithms | 2 | 2024 | 14098 | 0.030 |
Why?
|
Receptors, Transferrin | 1 | 2015 | 300 | 0.030 |
Why?
|
Psychotherapy | 1 | 2022 | 1653 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36582 | 0.030 |
Why?
|
Hepatectomy | 1 | 2016 | 589 | 0.030 |
Why?
|
Ferritins | 1 | 2015 | 601 | 0.020 |
Why?
|
Organ Size | 1 | 2016 | 2264 | 0.020 |
Why?
|
Survival Rate | 1 | 2024 | 12823 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 54886 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3667 | 0.020 |
Why?
|
Hemoglobins | 1 | 2015 | 1531 | 0.020 |
Why?
|
Adult | 4 | 2024 | 223317 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2024 | 15424 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2023 | 15824 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5875 | 0.020 |
Why?
|
Hospitalization | 1 | 2024 | 10815 | 0.010 |
Why?
|
Exercise | 1 | 2021 | 5954 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3851 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 10393 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 24299 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2015 | 12451 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41718 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26325 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39317 | 0.010 |
Why?
|
Young Adult | 1 | 2020 | 59980 | 0.010 |
Why?
|